Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Acologix's Series C: $25M For AC-820 Phase III Trial

Dec. 22, 2005

By Jennifer Boggs

Memory Gains $3.2M For Bipolar Work, Reports Positive AD Data

Dec. 21, 2005

By Jennifer Boggs

Onyx's Nexavar Wins FDA Approval In Kidney Cancer

Dec. 21, 2005

By Jennifer Boggs

Onyx's Nexavar Wins FDA Approval In Kidney Cancer

Dec. 21, 2005

By Jennifer Boggs

Memory Gains $3.2M For Bipolar Work, Reports Positive AD Data

Dec. 21, 2005

By Jennifer Boggs

Palatin Stops NeutroSpec Sales To Investigate Reported Deaths

Dec. 20, 2005

By Jennifer Boggs

Palatin Stops NeutroSpec Sales To Investigate Reported Deaths

Dec. 20, 2005

By Jennifer Boggs

ImaRx Adds $15M For Stroke Studies, Product Acquisition

Dec. 19, 2005

By Jennifer Boggs

ImaRx Adds $15M For Stroke Studies, Product Acquisition

Dec. 19, 2005

By Jennifer Boggs

MedImmune, Biota Deal: $112M For Small-Molecule RSV Drugs

Dec. 16, 2005

By Jennifer Boggs

MedImmune, which already markets Synagis to prevent respiratory syncytial virus in high-risk infants, made another investment in the RSV space by signing a $112 million deal to develop small-molecule compounds discovered by Australian company Biota Holdings Ltd. (BioWorld Today)